Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.61. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | LQD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $112.91 |
52-Week Low | $4.17 | $107.12 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, is trading at $108.67, showing minimal daily change. The technical outlook is bearish based on moving averages, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights strong investor flows into bond ETFs amid market uncertainty and rate hike speculation, positioning LQD as a core vehicle for investment-grade corporate bond exposure.
The outlook for LQD is tied to interest rate expectations and corporate credit health. The primary opportunity lies in its role as a liquid, diversified source of investment-grade yield, especially if rate hikes pause. Key risks include rising interest rates pressuring bond prices and potential credit spread widening if economic conditions deteriorate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
